Product Pipeline
12/17/2002 BEXXAR® receives strong support from FDA advisory panel
12/12/2002 Conference Call/Webcast Alert – Corixa to discuss ODAC Panel results on December 18, 2002
12/04/2002 Corixa and Kirin collaborate to develop potential WT1 cancer vaccine
12/02/2002 Corixa and GlaxoSmithKline provide BEXXAR® regulatory update
11/25/2002 ASH abstract: BEXXAR® produces a substantial number of durable complete responses
Abstract #1382 reports long-term follow-up from BEXXAR clinical trials
11/07/2002 Corixa reports third quarter results
11/07/2002 Genesis Research and Corixa provide PVAC™ treatment program update
Brazil and Cebu PVAC treatment psoriasis trials indicate clinical activity and safety
11/05/2002 Corixa and GlaxoSmithKline confirm BEXXAR® review by ODAC panel in December
11/05/2002 Conference Call/Webcast Alert - Corixa Corporation Third Quarter Earnings and Select Program Update Conference Call
10/28/2002 Corixa names Wayne Gombotz Vice President, Process Sciences and Pharmaceutical Development
10/03/2002 Corixa to present at UBS Warburg Global Life Sciences Conference
09/12/2002 Corixa technology may be useful for testing U.S. blood supply for presence of deadly parasite
08/12/2002 Corixa announces $45 million private placement financing
08/08/2002 Corixa reports second quarter results
08/07/2002 Conference Call/Webcast Alert
Corixa Corporation Second Quarter Earnings and Select Program Update Conference Call
06/27/2002 FDA grants Corixa's appeal for BEXXAR®
Corixa to present BEXXAR data at future ODAC meeting
06/06/2002 Corixa announces the initiation of additional PVAC™ treatment U.S. clinical trial
Randomized, blinded and controlled trial to evaluate reduction in disease severity in patients with mild to moderate psoriasis
05/31/2002 Corixa files request for formal dispute resolution with FDA on BEXXAR®
In its appeal, company requests appearance at ODAC meeting
05/23/2002 Medarex acquires "Ultra-Potent" antibody payload technology and product development programs from Corixa
05/23/2002 Corixa announces restructuring of its South San Francisco operations
Company to focus resources on core immunotherapeutic development efforts and related operations
05/15/2002 Corixa reports first quarter 2002 results and provides update on select programs
05/15/2002 Corixa announces results of BEXXAR® discussions with the FDA
Corixa to appeal recent Complete Review Letter and will request appearance at ODAC Meeting
05/14/2002 Conference Call/Webcast Alert
Corixa Corporation First Quarter Earnings and Select Program Update Conference Call
04/08/2002 Rhein Biotech and Corixa enter into license and supply agreement
03/25/2002 Corixa and GlaxoSmithKline respond to FDA Complete Review Letter for BEXXAR®
03/18/2002 Corixa and Ortho-Clinical Diagnostics collaborate to discover and develop breast cancer diagnostics
03/13/2002 Corixa receives Complete Review Letter on BEXXAR®
02/28/2002 Oncologic Drugs Advisory Committee endorses Corixa's Phase III trial design for Melacine melanoma vaccine
02/27/2002 Beckman Coulter and Corixa enter technology cross-license agreement
01/31/2002 Corixa reports strong fourth quarter and year-end results
Revenue in 2001 increased 57 percent
Results within provided earnings estimates
01/29/2002 Corixa Corporation 4th Quarter and Year-End 2001 Earnings Conference Call
01/15/2002 Corixa and Beaufour Ipsen collaborate to develop and commercialize Corixa's AnergiX.MG technology for the treatment of myasthenia gravis
01/15/2002 Corixa to present Melacine data and proposed Phase III trial design to the Oncologic Drugs Advisory Panel in February
01/09/2002 Corixa provides Bexxar regulatory update
01/08/2002 Corixa reports positive preliminary results for its Phase III pivotal trial of RC-529 synthetic adjuvant for use in preventing hepatitis B infection
Primary and secondary efficacy endpoints met with high degrees of statistical significance
A business overview as well as information on Corixa's partners, management team, employment opportunities, and company contacts.
Corixa's near-term products and adjuvant for research applications.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.
Company reports, stockholder letter, events calendar, stock quote, analyst list, and materials request.
Current and archived company press releases.
Current and archived company press releases.